Breaking AI & Tech News Analyzed

Bipartisan Push to Strip Section 224 from the 2026 NDAADemocratic Ro Khanna and Republican Thomas Massie have announced a joint amendment to delete Section 224, a clause that would create an “executive agent” to synchronize U.S. and Israeli defense‑technology programs. Their collaboration marks an unusual alliance between a progressive and a libertarian as they confront a provision many see as a backdoor to deeper military integration.What Section 224 Would Have MandatedThe provision requires the Secretary of Defense to designate an executive agent responsible for “synchronising cooperative efforts” between the United States and Israel, covering research, development, testing, evaluation, integration and industrial cooperation on defence technology.Creates a permanent liaison office within the Pentagon.Oversees joint AI‑driven surveillance, anti‑drone and anti‑tunnel projects.Blurs the line between foreign aid and joint R&D, potentially masking the cost of U.S. support.Financial Scale and Public SentimentThe 2026 National Defense Authorization Act totals roughly $1.15 trillion. While the bill contains a broader “Matters relating to Israel” section, Section 224 is singled out for its technology‑focused language.Recent polling by The New York Times and Siena College shows 57 % of U.S. voters oppose additional economic and military aid to Israel, and 62 % disapprove of the Israeli‑Palestinian conflict overall. The war in Gaza has already claimed more than 75,000 lives, fueling a historic low in American support for Israel.Political Ramifications for US‑Israel Defense TiesThe bipartisan effort underscores a growing willingness to question the “unconditional” nature of U.S. support. While some Republicans, such as Derrick Van Orden, label criticism of the measure as anti‑Semitic, others argue that the technology partnership could entangle U.S. forces in conflicts where Israeli tactics—such as the 2024 pager‑rigging incident—have caused civilian casualties.Khanna’s amendment also revives a broader anti‑war coalition that previously pushed for the release of Jeffrey Epstein files, indicating a strategic use of defense‑budget oversight to advance transparency and limit overseas entanglements.Outlook: What Happens Next in the Legislative ProcessIf the House Armed Services Committee adopts the amendment, the provision will face a floor vote where party leadership is expected to defend the broader Israel‑friendly provisions of the NDAA. However, the public backlash and the rare bipartisan front could force leadership to negotiate a compromise, possibly reshaping how future defence aid is structured—shifting from direct aid to more transparent, project‑based collaborations.Stakeholders to watch include the Pentagon’s Office of the Secretary of Defense, Israeli defence ministries, and advocacy groups on both sides of the aid debate. The next key dates are the committee markup scheduled for early June and the full House vote slated for late July.

The LeadA daily pill has shown remarkable results in doubling survival time for patients with pancreatic cancer, the world's deadliest form of the disease. According to clinical trial results presented at the American Society of Clinical Oncology's annual meeting, this breakthrough treatment represents a potential revolution in how we approach a cancer that has seen limited progress for decades.The Breakthrough Drug: DaraxonrasibThe drug in question, daraxonrasib, works by targeting a protein called Kras that fuels nearly all pancreatic cancers. This mechanism represents a significant advancement in treatment strategy, as Kras has been notoriously difficult to target effectively. The drug functions as a Ras(On) multi-selective inhibitor, capable of turning off the Kras protein to stop cancer growth regardless of which variant is present.Impressive Trial ResultsIn the clinical trial involving 500 patients with advanced pancreatic cancer, the results were striking. Those who took daraxonrasib lived an average of 13.2 months, compared to just 6.6 to 6.7 months for patients who received chemotherapy. This represents a near doubling of survival time, with the added benefit of fewer side effects compared to traditional chemotherapy treatments.Industry Impact and Expert ReactionsThe findings have been hailed as a "gamechanger" and "grand slam" by experts in the field. Dr. Rachna Shroff, chief of oncology at the University of Arizona Cancer Center, described the results as "landscape-changing" and "unprecedented survival." When she first read the trial results, conducted by researchers at the Dana-Farber Cancer Institute in Boston, she wept, noting the profound impact this could have on patients after 16 years of treating pancreatic cancer.Dr. Julie Gralow, Asco's chief medical officer, echoed these sentiments, calling the study a "home run" and suggesting it was actually a "grand slam" in terms of its significance.The Ras RevolutionOver 90% of patients with the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (mPDAC), have a mutation in the Kras gene. This discovery has long been considered the "holy grail" in cancer research, particularly for pancreatic cancer where the mutation is nearly ubiquitous and an early driver of cancer growth.Paula Hanford, chief executive of UK-based Pancreatic Cancer Action, called this one of the most significant developments in treatment she had ever seen. Similarly, Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK, described the results as "exciting," noting that the drug gives patients "months more precious time with their loved ones."Future Outlook and ApplicationsThe success of daraxonrasib opens doors for similar treatments targeting Ras genes in other cancers. Experts at the conference noted that because Ras genes fuel various types of cancer, there is hope for breakthroughs in treating lung and colon cancers as well, with similar drugs already in development for these conditions.However, challenges remain in ensuring these promising treatments become widely available to patients. As Jewell pointed out, tragically half of all people with pancreatic cancer die within just three months of diagnosis, making the rapid implementation of such treatments crucial.

The Call for Tax Cuts Wes Streeting has called for national insurance tax cuts for businesses, and for the government to drill for oil and gas in the North Sea. The former health secretary and Labour leadership candidate told the Sunday Times there should be a “targeted reduction” of employers’ national insurance contribution as a way to “actively incentivise” hiring, particularly of young people. The Impact of National Insurance Rate Increase In 2024, the rate of national insurance paid by employers was increased from 13.8% on each employee’s salary to 15%. The starting threshold it applied to was lowered from £9,100 to £5,000. The measure aimed to raise £25bn a year, but businesses said it disincentivised hiring lower-paid and part-time staff. Youth Unemployment Concerns A report this week by the former cabinet minister Alan Milburn said a lack of hospitality jobs was contributing to high youth unemployment in Britain. It pointed to a halving of vacancies in the hospitality industry over the past four years alone. Analysis shows Britain has the third-highest rate of 16- to 24-year-olds who are not earning or learning among rich European countries. The Government's Response Pat McFadden, the work and pensions secretary, suggested he disagreed with this view. Speaking on Sky News on Sunday morning, he defended the government’s record, saying that businesses already did not have to pay employers’ national insurance for workers under 21. The Future of North Sea Drilling There has been a debate within Labour about whether to grant drilling consents for the giant oil and gas fields Rosebank and Jackdaw. Though there was a commitment not to give out any more licences for fossil fuels in Labour’s manifesto, there is a loophole that could be exploited; Rosebank and Jackdaw were given exploration licences by the previous Conservative government. They just need consent to drill. Ed Miliband's Decision Ed Miliband, the energy secretary, is due to make a decision on these oil and gas fields in coming weeks. He, along with the North Sea Transition Authority, have to decide whether the drilling would be consistent with the UK’s climate commitments.

The Lead: Unprecedented Cancer Treatment SuccessDoctors have hailed "unprecedented" trial results that show a triple-action cancer jab can eradicate entire tumours in patients. In an international trial spanning 11 countries, the injection was offered to patients whose cancer had spread or come back and whose disease had failed to respond to other treatments.The Breakthrough: Amivantamab's Triple-Action ApproachThe jab, called amivantamab, shrank the tumours of more than a third of patients, with dramatic changes seen within weeks. In 15 of them, doctors found the drug had melted away their tumours altogether.The smart jab targets cancer in three ways. It blocks both EGFR (epidermal growth factor receptor), a protein that helps tumours grow, and MET, a pathway that cancer cells often use to escape treatment. It also helps activate the immune system to attack the tumour.The Clinical Trial Data: Impressive Response RatesIn the trial, 102 patients with head and neck cancer, the world's sixth most common cancer, were given the jab. Tumours shrank or disappeared completely in 43 patients, including 28 whose tumours shrank significantly and 15 who saw them eradicated entirely.Patients receiving amivantamab lived for a median of 12.5 months overall after starting treatment, despite having a form of cancer with very poor outcomes, once standard treatments stop working.The Impact Analysis: New Hope for Treatment-Resistant CancersKevin Harrington, professor in biological cancer therapies at the Institute of Cancer Research, London (ICR), said: "These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy. This is a group of patients for whom treatment options are extremely limited, so seeing this level of benefit is very striking."Researchers also highlighted that the trial focused on people with head and neck cancers that did not include those with human papillomavirus (HPV) positive oropharyngeal squamous cell carcinoma. That is particularly significant, they said, since head and neck cancers not caused by HPV are usually harder to treat, making progress in this group hugely important.The Patient Experience: Transforming Quality of LifeOne of the first patients to benefit was Carl Walsh, 56, who was diagnosed with tongue cancer in May 2024 and joined the OrigAMI-4 trial at the Royal Marsden in July 2025. "I was initially treated with both chemotherapy and immunotherapy, which unfortunately were not successful," he said. "At that point, I was recommended for the OrigAMI-4 trial. I'm now on my 17th cycle of treatment and I'm very pleased with the progress so far."Unlike many cancer treatments, amivantamab is given as a tiny jab under the skin rather than via an intravenous drip, making treatment quicker and more convenient for patients and much easier to deliver in outpatient clinics.The Future Outlook: Expanding Treatment ApplicationsThe results will be presented on Sunday in Chicago at the world's largest cancer conference, the annual meeting of the American Society of Clinical Oncology (Asco).Amivantamab, developed by Johnson & Johnson, is now being evaluated in about 60 clinical trials, primarily for lung cancer, but also for colorectal, brain and gastric cancers.Prof Kristian Helin, the chief executive of the ICR, said: "This study demonstrates how the development of new treatments through rigorous cancer research may lead to meaningful advances, even for patients with very limited treatment options. Achieving this level of tumour response and encouraging survival outcomes in such a challenging-to-treat group represents a significant step forward."

The Viral Image That Wasn't RealIt was an arresting image and an irresistible story. A group of tough Thai police officers – five men and one woman – all wearing elaborate festival-style dresses, surrounding a drug dealer they had caught while undercover. The image, released by local police, was so compelling that it found its way on to the front page of the UK's Daily Star, as well as in picture stories in the Telegraph, the Sun and the New York Post.The Sun wrote: "The burly crew of five men and one woman slipped into skin tight sequins and feathers for the covert mission in Thailand." The Daily Star wrote: "The team of five blokes and one woman shared a snap of themselves in frilly dresses with the nicked suspect on Facebook."There was just one problem: while the arrest was real, the image was an AI-generated fake.The Digital Deception Behind the Sparkly DressesThe real image, which has now been posted on the Facebook page of Tha Luang police station in Thailand, shows the five male police officers in their regular clothes. The woman dressed as a dancer is not in the original at all.The administrator in charge of the station's Facebook account, which released the AI-generated image, had been trying to create "a friendlier image" for the police, intending to show "a cute and humorous side". This attempt at humanizing law enforcement through digital manipulation inadvertently created a false narrative that spread internationally.The Media Verification Challenge in the AI EraThe absurdity of the image may have rung alarm bells with some readers. However, the fact that the faked image came from a seemingly official source has highlighted the difficulties media outlets face in verifying images.There are no foolproof ways to check whether an image is real without a direct relationship with the person who took the picture. It is becoming a time-consuming and precarious task for those overseeing the images used by large outlets, and AI verification tools are not reliable enough.Industry Implications for News OrganizationsThe problem is made even more difficult as the use of AI-generated imagery has crept into seemingly official sources. As a result, editors are braced for the reality that it is unlikely that all AI images will be spotted before publication.Media outlets and other organisations are also facing the opposite problem – with viewers wrongly suspecting that some genuine images have been generated with AI. This creates a credibility crisis where authentic content is increasingly questioned while manipulated content gains acceptance.The Future of Visual AuthenticationAs AI technology continues to advance, the line between real and fabricated content will become increasingly blurred. News organizations will need to invest in more sophisticated verification methods and potentially develop new standards for image authentication.The incident in Thailand serves as an early warning of the challenges ahead in maintaining journalistic integrity in an era where digital content can be convincingly altered with minimal technical skill. The media industry may need to adopt new protocols for image verification and be more transparent about the sources of their visual content.

The LeadFormer and current workers on Married at First Sight UK have come forward with allegations of a "toxic" production culture that placed an "unhealthy" focus on whether cast members were having sex, adding to the growing controversy surrounding the hit Channel 4 reality show. These claims emerge after multiple female cast members alleged they were raped by their on-screen partners, with a third woman claiming she was the victim of a nonconsensual sexual act.The Production Culture RevelationsAccording to reports from the BBC, former crew member Soraya Spiers described the culture on the show as "toxic from the top down." She specifically criticized the emphasis on sex as "unhealthy," noting that unlike real-life dating where individuals can leave uncomfortable situations, cast members on the show face greater pressure to comply with expectations."On the wedding night, there's an expectation, for those of us who were working on the show, that you should get some sort of hint if the couples are going to sleep together," Spiers said. "Even though they've only known each other for two seconds by that point."Another anonymous former staff member revealed that senior producers would express concerns if couples were not having sex, stating "it wasn't good for storylines." Additional concerns were raised about cast members having access to excessive alcohol during production.The Industry ImpactThe allegations have sparked significant debate within the TV industry about whether the Married at First Sight format, with its expectation of rapid intimacy, can guarantee the safety and wellbeing of participants. Several former contributors and staff have expressed doubts about the show's ability to maintain appropriate boundaries in its current format.Channel 4 has responded by launching two separate investigations: one focused on the show's handling of the complaints it received, and another examining whether welfare protocols should be changed for future productions. The broadcaster emphasized that "contributor welfare is always our primary concern across all productions."The production company CPL, which creates the show, has defended its practices, stating they have "gold-standard welfare policies" and that contributors are "not pressured in any way or expected to be intimate." CPL also claimed to have an "alcohol protocol" with clear guidance on consumption, though former workers dispute the effectiveness of these measures.The Future of Reality TV ProductionAs investigations continue, the Married at First Sight controversy may prompt broader changes in how reality TV productions approach participant welfare, particularly in shows that involve intimate relationships and rapid emotional connections. The industry may face increased pressure to implement more robust safeguarding measures and to reconsider formats that potentially exploit vulnerable participants for entertainment value.The revelations also highlight the growing accountability of broadcasters and production companies for creating safe working environments, both for cast members and production staff. As the investigations unfold, the outcomes could set precedents for how similar reality shows are produced and regulated in the future.

The World Health Organization (WHO) is deploying its highest leadership to the Democratic Republic of the Congo (DRC) as the nation grapples with its 17th Ebola outbreak, a crisis exacerbated by the absence of approved vaccines for the specific viral strain. The Strain of Survival: Lack of Vaccines for Bundibugyo The current outbreak is caused by the Bundibugyo strain, a distinct variant from the more common Zaire strain. This distinction is critical because while previous DRC outbreaks had established vaccines and treatments, the Bundibugyo strain currently has no approved vaccines or treatments. WHO Director-General Tedros Adhanom Ghebreyesus emphasized the critical role of health workers in Bunia, the capital of Ituri province, stating they are the "backbone of this response." As of the latest reports, one patient has recovered, offering a glimmer of hope amidst the challenges. Quantifying the Crisis: Confirmed Cases and Regional Spread The scale of the outbreak is significant, with latest government figures revealing a total of 1,077 suspected cases and 246 suspected fatalities. The confirmed data shows 121 confirmed cases and 17 confirmed deaths, though authorities estimate the true number of casualties may be higher. The crisis has not been contained within DRC borders; Uganda has confirmed eight cases, including one death, prompting the government to close its borders for at least four weeks. Confirmed Cases: 121 Confirmed Deaths: 17 Suspected Cases: 1,077 Suspected Fatalities: 246 Ugandan Cases: 8 Geopolitical and Logistical Barriers to Containment Containment efforts are severely hampered by logistical shortages and regional instability. Health workers are operating with scant supplies, resorting to wearing expired medical masks in some areas. Furthermore, the volatile security situation in eastern DRC, where armed groups vie for power, has led to attacks on health centers and public distrust of authorities. The WHO chief made a direct appeal to these armed groups, urging a brief ceasefire to allow health workers to operate safely. The Race for a Vaccine and a Ceasefire The global community is mobilizing resources to combat the spread. The DRC government has released $20m to fund the response, while the United States has allocated an additional $80m, bringing total US aid to $112m. On the scientific front, the Africa Centres for Disease Control and Prevention (Africa CDC) has pledged to have a vaccine and medicine ready against the Bundibugyo strain by the end of 2026. Until then, experimental treatments will be used strictly in clinical trials, highlighting the urgent need for scientific breakthroughs to match the speed of the virus's spread.

The Lead: This Week's Entertainment HighlightsThis week's entertainment landscape offers a diverse array of critically acclaimed shows and films, from hilarious comedies to chilling horror. Channel 4's "Make That Movie" stands out as one of the funniest shows of the year, while Netflix's "The Four Seasons" returns with a brilliant second season. Horror fans can explore the disturbing world of "Backrooms," while Marvel offers a stylish take with "Spider-Noir."TV Comedy Gold: Make That MovieChannel 4Summed up in a sentence Last One Laughing finalist delivers one of the funniest shows of the year, with this mockumentary about a director who makes awful films.What our reviewer said "So ostentatiously silly that it deserves to be paraded around the streets." Stuart HeritageRead the full reviewFurther reading "People are like: you're a crackpot": how Sam Campbell became comedy's oddball superstarNetflix Triumph: The Four Seasons ReturnsNetflixSummed up in a sentence Tina Fey triumphs again with the return of this comedy about a group of middle-aged friends who reunite during holidays throughout the year.What our reviewer said "Even more perspicacious, poignant and hilarious than the first." Chitra RamaswamyRead the full reviewMarvel's Stylish Take: Spider-NoirPrime VideoSummed up in a sentence In Marvel's witty homage to the hard-boiled films and fictions of the 40s – which can be watched in colour or black-and-white – Nicolas Cage plays Ben Reilly, who gave up being superhero "the Spider" five years ago.What our reviewer said "Everything is shot with style and confidence." Lucy ManganRead the full reviewFurther reading The life of PIs: the strange case of 2026's resurgence of hard-boiled detectivesHidden Gem: PoniesNow/Sky AtlanticSummed up in a sentence Emilia Clarke and Haley Lu Richardson have heaps of fun as two widows who become cold war spies in this espionage comedy-drama.What our reviewer said "It's a mashup of genres and tropes, but it is its own thing too – and an unexpected treat at that." Lucy ManganRead the full reviewHorror Innovation: BackroomsIn cinemas nowSummed up in a sentence A debut from 20-year-old director Kane Parsons that examines memory, reality and fear in an icily disturbing horror, in which Chiwetel Ejiofor accesses an infinite series of hidden rooms that all feel creepily askew.What our reviewer said "Backrooms progressively raises its game towards the big finish with jump scares, squirm scares and tiny shiver scares. There is real fascination in exploring this vast, invisible city state of fear." Peter BradshawRead the full reviewFurther reading Are you sitting uncomfortably? How Backrooms upended the horror movieMusic and Bromance: Power BalladIn cinemas nowSummed up in a sentence Nick Jonas and Paul Rudd star in a comedy of bromance and betrayal from Irish writer-director John Carney that brilliantly brings together Rudd's washed-up wedding singer and Jonas's insecure ex-boyband superstar.What our reviewer said "Power Ballad is about making it and dreaming big, about every busker never giving up on hopes of one day being mega. But as so often with Carney, it's about something else, usually left unacknowledged in movies about music or any sort of show business: the terrible binary of success and failure." Peter BradshawRead the full reviewUnexpected Pairing: TunerIn cinemas nowSummed up in a sentence Playing a piano tuner with super-sensitive hearing, Leo Woodall's relationship with Dustin Hoffman is a tender highlight in this safe-cracking thriller.What our reviewer said "What a pair they are; they are a real pleasure to watch in an easy, unforced drama that mixes romcom moments with a relaxed crime thriller. It's like the Safdie brothers in chill-out mode." Cath Clarke

Gluten‑Free Bread Prices Edge Toward £4 Consumers with coeliac disease are facing a new financial hurdle: a branded 480 g gluten‑free loaf, such as Promise, now retails at £3.90 in major supermarkets, edging close to £4. By contrast, a regular 800 g white loaf remains under £1. The price gap is prompting alarm that a medically‑necessary diet is turning into a luxury. Price Data Shows Double‑Digit Increases Across Staples Typical 550 g gluten‑free loaf: £1.90 (vs. £0.99 for standard bread). Current average gluten‑free loaf price: £3.12, up 17p (≈6%) since May 2025. Gluten‑free flour: >10% rise to £3.80 (up 36p). Gluten‑free cornflakes (300 g): £1.80 vs. regular 500 g at ~£0.90. Eight‑pack free‑from biscuits: £1.60 vs. regular 30‑pack at £0.65. Weekly gluten‑free shop can be up to 35% more expensive than a standard shop (Coeliac UK research). Rising Costs Threaten Accessibility for Coeliac Consumers Experts link the price surge to several factors: Higher production costs for dedicated gluten‑free facilities. Stricter testing regimes demanded by retailers. Broader food‑price inflation driven by the Iran‑Ukraine conflict, with overall food price growth projected to near 10% by year‑end. Surveys from Mintel reveal that affordability influences diet choices: about 14% of financially comfortable consumers follow a gluten‑free diet, falling to 8% among those on tighter budgets. In April, 59% of shoppers said rising supermarket prices were affecting them, leading many to reconsider specialist products. What Future Price Trajectories Could Mean for the Free‑From Market If inflation persists, analysts warn that: Retailers may reduce the range of gluten‑free items, as seen by a drop from 19% to 12% of new food launches between 2019 and 2025. Manufacturers like Eurostar Commodities could face tighter margins, limiting investment in new gluten‑free products. Policy pressures may increase, especially as the UK government’s withdrawal of adult prescriptions for gluten‑free bread and flour adds strain on households. Supermarkets such as Tesco assert a commitment to keep free‑from prices affordable through Everyday Low Prices and Clubcard discounts, while brands like Doves Farm aim to maintain flour prices between £1.84 and £1.95. The coming months will reveal whether these measures can offset the upward cost trend and preserve access to essential gluten‑free foods.